Literature DB >> 15762884

Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation.

I Desombere1, T Cao, Y Gijbels, G Leroux-Roels.   

Abstract

The mechanisms causing non-responsiveness to hepatitis B surface antigen (HBsAg) vaccines in man remain elusive. The increased incidence of non-responsiveness in subjects with HLA-DR3(+) or -DR7(+) haplotypes suggests that immune response mechanisms governed by genes of the MHC are involved. Homozygotes for these two haplotypes are found almost exclusively in the non-responder (NR) population. It is conceivable that antigen-presenting cells (APC) of NR are defective in the uptake of HBsAg and that they are unable to present this Ag adequately. Previously, we demonstrated that DR2(+), DR7(+) and DP4(+) NR were able to present HBsAg. In the present paper we demonstrate that six DR0301(+) NR, five of which are homozygous for this marker, were able to take up, process and present HBsAg to HBsAg-specific, DR0301-restricted T cell lines. Non-fractionated peripheral blood mononuclear cells (PBMC) from the DR0301(+) NR did not proliferate to HBsAg in vitro, whereas they proliferated vigorously upon stimulation with tetanus toxoid, thus ruling out the presence of a generalized immunodeficiency. We therefore conclude that HLA-DR0301(+) NR vaccinees are not deficient in their HBsAg-presentation. Because it was demonstrated that recently activated T cells can apparently bypass the requirement for B7, we may have overlooked the role of the B7-co-stimulation in our set-up that used HBsAg-specific T cell lines. Therefore we examined the expression of B7 co-stimulatory molecules on NR-APC. CD86 was normally present on these cells and was not down-regulated after culturing the PBMC in the presence of HBsAg. We conclude that CD86 expression on CD14(+) monocytes of DR0301- and DR07-homozygous poor responders is not deficient and cannot be the mechanism underlying the non-responsiveness of these subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15762884      PMCID: PMC1809328          DOI: 10.1111/j.1365-2249.2004.02749.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  Functional responses and costimulator dependence of memory CD4+ T cells.

Authors:  C A London; M P Lodge; A K Abbas
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  Two distinct pathways of human macrophage differentiation are mediated by interferon-gamma and interleukin-10.

Authors:  T Orlikowsky; T Olikowsky; Z Q Wang; A Dudhane; H Horowitz; B Conti; M K Hoffmann
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

Review 3.  CD28/B7 costimulation: a review.

Authors:  E A Greenfield; K A Nguyen; V K Kuchroo
Journal:  Crit Rev Immunol       Date:  1998       Impact factor: 2.214

4.  Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen.

Authors:  S Caillat-Zucman; J J Gimenez; F Wambergue; G Albouze; B Lebkiri; C Naret; A Moynot; P Jungers; J F Bach
Journal:  Kidney Int       Date:  1998-06       Impact factor: 10.612

5.  The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg.

Authors:  T Höhler; C U Meyer; A Notghi; B Stradmann-Bellinghausen; P M Schneider; R Starke; F Zepp; R Sänger; R Clemens; K H Meyer zum Büschenfelde; C Rittner
Journal:  Hum Immunol       Date:  1998-04       Impact factor: 2.850

6.  Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults.

Authors:  G Leroux-Roels; I Desombere; G De Tollenaere; M A Petit; P Desmons; P Hauser; A Delem; D De Grave; A Safary
Journal:  Vaccine       Date:  1997-11       Impact factor: 3.641

7.  Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens.

Authors:  Z Yi-qun; R J Joost van Neerven; A Kasran; M de Boer; J L Ceuppens
Journal:  Int Immunol       Date:  1996-01       Impact factor: 4.823

8.  Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination.

Authors:  A B McDermott; J N Zuckerman; C A Sabin; S G Marsh; J A Madrigal
Journal:  Tissue Antigens       Date:  1997-07

9.  Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines.

Authors:  G Leroux-Roels; I Desombere; L Cobbaut; M A Petit; P Desmons; P Hauser; A Delem; D De Grave; A Safary
Journal:  Vaccine       Date:  1997-11       Impact factor: 3.641

10.  Response to hepatitis B vaccine: multiple HLA genes are involved.

Authors:  I Desombere; A Willems; G Leroux-Roels
Journal:  Tissue Antigens       Date:  1998-06
View more
  8 in total

1.  T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals.

Authors:  Martin R Weihrauch; Michael von Bergwelt-Baildon; Milos Kandic; Martin Weskott; Winfried Klamp; Joachim Rosler; Joachim L Schultze
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 2.  Searching for the human genetic factors standing in the way of universally effective vaccines.

Authors:  Alexander J Mentzer; Daniel O'Connor; Andrew J Pollard; Adrian V S Hill
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

3.  KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection.

Authors:  Lei Shi; Jia M Wang; Jun P Ren; Yong Q Cheng; Ruo S Ying; Xiao Y Wu; Shu M Lin; Jeddidiah W D Griffin; Guang Y Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Immunol       Date:  2013-12-13       Impact factor: 5.422

4.  Effect of revaccination using different schemes among adults with low or undetectable anti-HBs titers after hepatitis B virus vaccination.

Authors:  Chao-Shuang Lin; Shi-Bin Xie; Jing Liu; Zhi-Xin Zhao; Yu-Tian Chong; Zhi-Liang Gao
Journal:  Clin Vaccine Immunol       Date:  2010-08-18

5.  Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen.

Authors:  Isabelle Desombere; Annick Willems; Yvonne Gijbels; Geert Leroux-Roels
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 6.  Immune exhaustion and immune senescence: two distinct pathways for HBV vaccine failure during HCV and/or HIV infection.

Authors:  Zhi Q Yao; Jonathan P Moorman
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-02-12       Impact factor: 4.291

7.  Immunologic hypo- or non-responder in natural dengue virus infection.

Authors:  Guey Chuen Perng; Kulkanya Chokephaibulkit
Journal:  J Biomed Sci       Date:  2013-05-31       Impact factor: 8.410

8.  Host genetic factors and vaccine-induced immunity to hepatitis B virus infection.

Authors:  Branwen J Hennig; Katherine Fielding; John Broxholme; Mathurin Diatta; Maimuna Mendy; Catrin Moore; Andrew J Pollard; Pura Rayco-Solon; Giorgio Sirugo; Marianne A van der Sande; Pauline Waight; Hilton C Whittle; Syed M Zaman; Adrian V Hill; Andrew J Hall
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.